MedTrace Logo

Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma

NCT05552651 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-09-23

No results posted yet for this study

Summary

The objective is to investigate the efficacy and safety of envafolimab combined with chemotherapy for preoperative neoadjuvant therapy in patients with resectable esophageal squamous cell carcinoma

Conditions

Interventions

DRUG

Envafolimab

300mg,sc,d1,Q3W;

DRUG

Albumin-Bound Paclitaxel

130mg/m2,iv,D1,D8,Q3W

DRUG

Carboplatin

AUC=5, iv,D1,Q3W

Sponsors & Collaborators

  • Tao Jiang

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-20
Primary Completion
2023-12-20
Completion
2023-12-20

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05552651 on ClinicalTrials.gov